ENGINEERINGNET.EU -- Dr. Cauwenbergh brings more than 30 years of experience in the pharmaceutical industry, including a successful track record developing and commercializing dermatological drugs. He will also serve as a director on the Company’s board.
Prior to joining RXi, he served as Chairman and Chief Executive Officer of Barrier Therapeutics, a publicly-traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development.
Barrier was acquired by Stiefel Laboratories in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years.
As Vice President R&D for Johnson & Johnson’s Skin Research Center, he was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies.
Dr. Cauwenbergh received his Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine (Belgium), where he also completed his masters and undergraduate work.
BACKGROUND
RXi Pharmaceuticals Corporation is a biotechnology company focused on innovative therapies based on its proprietary, next-generation RNAi platform.
Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to “silence,” or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.
Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi’s first RNAi product candidate, which targets CTGF (connective tissue growth factor), is scheduled to commence human clinical trials for scar prevention in 2012.
